Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Net working capital generated approximately $27 million of cash in the quarter and resulted in a positive contribution to cash flow for the full year |
| Early results from the ec2 acquisition are encouraging and the integration is proceeding on pace |
| 2023 was a good year and we are building on that momentum in every corner of the enterprise |
| We delivered a record year for the company and I'm proud of the progress we've made as a team while continuing to build a great business |
| First, we closed out 2023 with record backlog generated by fourth quarter organic order growth of 30% |
| This is our sixth consecutive quarter backlog expansion, reflecting growth of 15% compared to year-end 2022 |
| Our vertical markets are healthy and I'm encouraged by our top line coverage heading into 2024 |
| It was a great year for you guys, over 20% growth in orders |
| First, our top line growth is visible, supported by robust order growth, healthy markets and a record backlog |
| I think the thing to think about here is this year was specifically a nuclear power candidly, just a very good year |
| In closing, we had a really solid year in 2023 and certainly a strong finish in the fourth quarter |
| I'm extremely proud of the team's execution against the cash and leverage targets we laid out early in 2023 |
| And this performance bolsters our confidence and sustained momentum in this area in 2024 |
| We feel very good coming into 2024, about overall market dynamics, the top line support that will accrue from that |
| Beginning with the Medical segment and specifically our Radiation Therapy business, we remain encouraged by the positive momentum we've generated in the European market by bolstering our sales and support capabilities in the region |
| We think we'll continue to see good momentum in this business |
| Our digital and new product portfolios remain key areas of focus for growth and we expect a strong 2024 in radiation therapy |
| Within Occupational Dosimetry, the business remains well-positioned as we commercialize the next generation of Instadose technology this year |
| Core services and hardware demand remain well supported heading into the New Year |
| Lastly, recent trends in the Nuclear Medicine market continue to support our belief that this segment will be a strong growth engine for us |
| So overall, again, very positive statement |
| Our early experience confirms the view that ec2 will meaningfully improve Mirion's position to meet the growing demand stemming from theranostic applications for cancer care |
| This revolution in nuclear medicine is enhancing the ability for physicians to more accurately image, diagnose and treat cancer, yielding improved patient outcomes and reduced treatment costs |
| Price-cost initiatives, inclusive of a heavier focus on material and indirect spend, higher volumes and product mix, are all anticipated to be positive drivers for adjusted EBITDA margin expansion |
| 2023 order growth was extremely robust, supported by the large orders we reported in Q3 |
| The installed base remains a strong driver and an important focal point of sustained and defensible growth for Mirion going forward |
| We are encouraged by the global pipeline of new build opportunities and expect to take advantage of the growing and accelerated commitment to utility-scale nuclear power |
| And with the acquisition of ec2, it gives us the opportunity, firstly, to benefit more richly from, again, volumetric growth and procedures |
| Something we strongly believe in and support |
| I think the biggest thing to recognize is the order growth gives us confidence in being able to deliver |
| Statement |
|---|
| Margin degradation was driven again by our French business, which experienced a number of challenges in the fourth quarter, including product mix headwinds and a broader operational challenges |
| The SIS acquisition negatively impacted adjusted EBITDA margins by approximately 120 basis points |
| Our full year adjusted EBITDA margin in Technologies contracted by 160 basis points to 26.2% |
| Technologies adjusted EBITDA margin contracted by 70 basis points versus the fourth quarter last year to 29.5% |
| And understand that in the French market in particular, as the dominant customer in country, EDF has gone through struggles that has had some attendant impact on some of our execution capabilities and just predictability of that business |
| So for us, it's down to execution |
| You mentioned that it impacted your margins by about 120 basis points for the entire year |
| As we've talked about all year, the net impact of acquiring SIS and divesting Biodex impacted margins by approximately 70 basis points |
| Brian Schopfer I think on SIS, a couple of things, right? One, that margin contraction on our end was planned, right, because we comped seven months without having it |
| So that certainly is a factor in the disproportionate international growth that we're seeing in the sector that has offset domestic conditions that have been a little bit softer, in part because of margin compression or inversion on the part of the US healthcare providers in this post-pandemic era |
| And when we bought this business, we knew it was a little bit of a fixer-upper that we needed to do |
| I'm curious, two things |
| This business was comping 24% organic growth from Q4, 2022 |
| First, on the Medical side, can you maybe talk about some of the headwinds we are facing in the healthcare industry? As the Medicare physician fee schedule increases, do you see an impact to the Radiation Therapy Quality Assurance part of the business? You touched some on the new clinic versus volume increase |
| In addition, there have been a series of kind of one-off events that are non-recurring in nature that we don't expect to have any bearing on our corrective action pathways as we move ahead |
| As it relates to Medical and your specific question about headwinds coming from CMS and Medicare reimbursement, as it relates to RTQA, in the broader context when we think about the RTQA or Radiation Therapy Quality Assurance business, which is today about half of our total medical revenue |
| But I think we're doubling down this year on cost |
Please consider a small donation if you think this website provides you with relevant information